In a turbulent market, experts recommend five stocks with strong technical indicators for short-term investments. From ...

Following the earnings announcement, several brokerage firms revised their target price for the stock, with some estimates ...

Nuvama has maintained a ‘Hold’ rating, raising its target price from Rs 1,620 to Rs 1,651. The brokerage cited strong ...

Aurobindo, Cipla and Viatris will develop, manufacture and supply long-acting injectable cabotegravir. Aurobindo, Cipla and ...

The drugmaker posted a profit of Rs 1,298 crore in the quarter-ended June, according to an exchange filing on Friday.

The market may continue to consolidate with a negative bias in the upcoming sessions. Below are some short-term trading ideas ...

With the stock showing a rise of 2.09%, Cipla continues to be a key player in the pharmaceutical sector, demonstrating steady financial performance and active corporate actions.

Cipla share price gain 3% after Q1 earnings beat estimates, with strong margins, India growth, and positive analyst sentiment ...

Cipla, the country’s third-largest drugmaker by market value, was the top gainer on the Nifty 50 on Friday, rising over 3 per ...

Cipla Ltd (BOM:500087) reports robust financial performance with significant milestones in India and strategic advancements in the US market.

Cipla , India's third-largest drugmaker by sales, reported a better-than-expected quarterly profit on Friday, driven by higher domestic demand for its generic respiratory drugs.

Cipla consolidated net profit for the quarter ending June 2025 at ₹1291.61 crore was up 10% compared to ₹1175.46 crore in the ...